RecruitingNot ApplicableNCT07410637

Impact of Thyroid Hormones on Human Glucose and Energy Metabolism


Sponsor

University of Ulm

Enrollment

60 participants

Start Date

Feb 4, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial to clarify the impact of changes in thyroid hormone levels on glucose and lipid metabolism. Patients will be included in whom thyroid hormone levels are intentionally changed by treatment. In patients with Graves' disease, thyroid hormone levels will be lowered using medication, while in patients with thyroid cancer, thyroid hormone levels will be raised using medication. Oral glucose tolerance tests will be performed before treatment and at two time points after treatment begins to assess metabolic effects.


Eligibility

Plain Language Summary

Simplified for easier understanding

This study examines how thyroid hormones affect the way the body processes glucose (blood sugar) and manages energy in patients with either Graves' disease (an overactive thyroid) or thyroid cancer. **You may be eligible if...** - You have been newly diagnosed with Graves' disease (an immune condition causing an overactive thyroid), OR - You have been diagnosed with thyroid cancer **You may NOT be eligible if...** - You have diabetes mellitus - Your fasting blood sugar is 200 mg/dL or higher - You currently use insulin that is still active in your body at the time of the test - You have an acute illness that is activating stress hormones - You are in a post-surgical recovery or acute infection state Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHEROral Glucose Tolerance Test

Participants will receive a 75 g oral glucose tolerance (3h) before the start of treatment, two weeks and three months after start of treatment. Body composition will measured by bioimpedance analysis. Before and during the oral glucose tolerance test, indirect calometry will assess metabolic flexibility.


Locations(1)

Ulm University Hospital

Ulm, Baden-Wurttemberg, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07410637


Related Trials